Quarterly Report • May 7, 2014
Quarterly Report
Open in ViewerOpens in native device viewer
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Sales | 3,201 | 3,212 |
| Adjusted EBITDAa | 463 | 606 |
| Adjusted EBITDA margin in % | 14.5 | 18.9 |
| Adjusted EBITb | 316 | 464 |
| EBIT | 288 | 434 |
| Income before financial result and income taxes, continuing operations | 279 | 421 |
| Net income | 166 | 293 |
| Earnings per share in € | 0.36 | 0.63 |
| Adjusted earnings per share in € | 0.40 | 0.65 |
| Cash flow from operating activities, continuing operations | 322 | 184 |
| Capital expenditures | 209 | 178 |
| Net financial assets/debt as on the balance sheet as of March 31 | 583 | –1,137 |
| Employees as of March 31 | 33,651 | 33,455 |
Prior-year figures restated.
a Earnings before interest, taxes, depreciation, and amortization, after adjustments.
b Earnings before interest and taxes, after adjustments.
Due to rounding, some figures in this report may not add up exactly to the totals stated.
| Evonik in focus Q1 2014 | 3 |
|---|---|
| Evonik on the capital markets | 4 |
| Profile of Evonik | 6 |
| Quarterly financial report | 7 |
|---|---|
| Interim management report | 8 |
| Interim financial statements | 24 |
| Financial calendar | 46 |
| Credits | 46 |
Daimler AG and Evonik have restructured their activities in the field of electric mobility in Kamenz and Kirchheim unter Teck (Germany) in response to altered market conditions. Evonik has sold its 50.1 percent interest in Li-Tec Battery GmbH and its 10 percent stake in Deutsche Accumotive GmbH & Co. KG to Daimler AG, making it the sole owner of these two companies. The parties agreed not to divulge details of the agreement, which was concluded at the end of March 2014.
Evonik is building the world's first production plant for AQUAVI Met-Met in Antwerp (Belgium). This new source of methionine has been specially developed for shrimp and other crustaceans and is added to the feed used in aquaculture. The plant, which will be operated by the Health &
Nutrition Business Unit, is scheduled come on stream at the end of 2015. Investment will be in the lower double-digit million euro range. AQUAVI Met-Met is an ideal addition to our product portfolio for aquaculture and opens up new growth prospects for Evonik. We will initially be marketing it for shrimp and crustaceans. Use with other species will follow.
Evonik has successfully started operation of a new production facility for ROHACELL structural foam at its site in Darmstadt (Germany) following investment of approximately €6 million. This new facility for
the Performance Polymers Business Unit increases polymerization capacity at the site by about 50 percent in response to rising demand. ROHACELL is an extremely robust structural foam used as a core material in heavy-duty sandwich structures for the aviation, aerospace and automotive industries and lifestyle applications. For example, it is used in components for the Airbus A340 and A380 and in the manufacture of rotor blades for helicopters.
At the end of February 2014, Evonik acquired Silbond Corporation, Weston (Michigan, USA), a specialized supplier of silicic acid esters (TEOS). This strengthens our leadership in silanes and improves our technology and cost position. The purchase price was in the mid double-digit million euro range. Silicic acid esters are a special group of functional silanes used in a wide variety of high-growth applications, for example, in the electronics industry. The acquisition opens the door for our Inorganic Materials Business Unit to supply TEOS from local production, especially to customers in North America, and to participate in future growth in the market for silicic acid esters.
In mid-March 2014, Evonik signed an agreement to divest its global line of skin-care activities for professionals, bundled under the Stoko Professional Skin Care brand, to the Deb Group of the UK, the world leader in skin care regimes for the workplace and public environments. This opens up further growth prospects for the Stoko product line, which was previously part of the Consumer Specialties Business Unit. Details of the agreement have not been disclosed.
In the first few weeks of January 2014, Evonik shares continued the upward trend seen at the end of 2013. Having started the year at €29.61 on January 2, the share price subsequently rose above the €30 mark several times. The Q4 and full-year results for 2013, which were published on
March 7, 2014, were in line with capital market expectations. They were therefore wellreceived and our share proved robust on this date, despite the negative market environment.
In the second half of March the share price dropped to between €26 and €27. This was caused partly by the revision of analysts' expectations for Evonik in 2014, and partly by the fact that equity markets around the world were affected by the Crimea crisis and fears that the Chinese economy could be cooling. The share price recovered at the end of the month and ended the first quarter of 2014 at €28.28. Overall, the share price declined by 4.6 percent in the first three months of this year, while the MDAX and DJ STOXX 600 ChemicalsSM slipped 0.7 percent and 1.0 percent respectively.
Evonik has a long-term dividend policy that takes account of the legitimate dividend expectations of our shareholders without curtailing corporate growth. At the Annual Shareholders' Meeting on May 20, 2014, the Executive Board and Supervisory Board will propose a dividend of €1.00 per share, an increase of €0.08 or 9 percent compared with the previous year. We are therefore offering a dividend yield of over 3 percent, which is among the highest in the chemical industry. Dividend continuity is an important objective for us. Evonik intends to pay an attractive dividend to its shareholders in the future too.
| Jan. 1 – Mar. 31, 2014 | |
|---|---|
| Highest share pricea in € | 30.45 |
| Lowest share pricea in € | 26.40 |
| Average pricea in € | 28.50 |
| Closing pricea on March 31, 2014 in € |
28.28 |
| No. of shares | 466,000,000 |
| Market capitalizationa on March 31, 2014 in € billion |
13.18 |
| Average daily trading volumea No. of shares |
183,589 |
| WKN | EVNK01 |
|---|---|
| ISIN | DE000EVNK013 |
| Ticker symbol | EVK |
| Reuters (Xetra trading) | EVKn.DE |
| Bloomberg (Xetra trading) | EVK GY |
| First trading day | April 25, 2013 |
| Trading segments | Regulated market (Prime Standard), Frankfurt am Main |
| Regulated market, Luxembourg | |
| Indices | MDAX, STOXX Europe 600 |
a Xetra trading.
Evonik DJ STOXX 600 Chemicals SM (indexed)
Alongside investors' conferences at the start of the year, our investor relations activities in the period January to March 2014 focused principally on reporting on fiscal 2013 and the fourth quarter of the year. The subsequent roadshows to financial centers in Europe attracted a good deal of interest. Overall, we registered around 100 contacts with investors in the first quarter of 2014.
Two further analysts initiated coverage of Evonik in the reporting period. Our stock is now covered by 19 analysts. Eight of them rated Evonik as a buy, three put it on sell and eight issued hold recommendations. Their price targets ranged from €23 to €34. The median at the end of the quarter was €31.20.
Our largest shareholders in the reporting period were still RAG-Stiftung, with a shareholding of 67.9 percent of the capital stock, and funds advised by CVC Capital, with an indirect shareholding of 17.9 percent. The free float was 14.2 percent.
To enable our employees to share in the success of the company and strengthen the focus on the capital markets, Evonik launched the Share.2014 employee share program in March. We reported regularly on our Investor Relations website on the repurchase of shares for this purpose.
a The shares in Evonik are held by Gabriel Acquisitions GmbH, an indirect subsidiary of funds advised by CVC Capital Partners.
On March 28, 2014 the international rating agency Moody's confirmed our Baa2 rating (outlook: positive). Moody's specifically highlighted the backward integration of our production processes and our above-average profitability. Further, it stressed the strong debt reduction of around €3.1 billion resulting from the divestment of the majority shareholding in our real estate company Vivawest. Our current rating from Standard and Poor's is BBB+ with a stable outlook. Evonik therefore has sound investment-grade ratings. Maintaining these is a central element in our financial strategy.
For further information on our investor relations activities, visit our website at www.evonik.com/ investor-relations. The financial calendar on our website provides a convenient overview of important dates, plus key facts and figures, especially financial and segment data and details of the company's structure and organization.
This is supplemented by information on Evonik shares, the terms of bond issues and an overview of our credit ratings. Current presentations, analysts' estimates and reports on our business performance are also available.
Evonik is one of the world's leading specialty chemicals companies. The central elements of our strategy for sustained value creation are profitable growth, efficiency and values. Around 80 percent of sales come from market-leading positions, which we are systematically expanding. We concentrate on high-growth megatrends, especially health, nutrition, resource efficiency and globalization. As part of our ambitious growth strategy, we are also stepping up our presence in emerging markets, especially in Asia. Important competitive advantages come from our integrated technology platforms, which we continuously refine. Our operations are grouped in three segments, each of which has two business units.
The segment produces specialty chemicals, principally for applications in the consumer goods, animal nutrition and pharmaceutical sectors. It comprises the Consumer Specialties and Health & Nutrition Business Units.
The Resource Efficiency segment provides solutions for environment-friendly and energy-efficient products. It comprises the Inorganic Materials and Coatings & Additives Business Units.
The heart of the Specialty Materials segment is the production of polymer materials and their preproducts, and additives. It comprises the Performance Polymers and Advanced Intermediates Business Units.
This segment principally comprises site services and business services. It mainly provides services for Evonik's specialty chemicals segments and Corporate Center, but also serves third parties.
| Interim management report | 8 |
|---|---|
| 1. Business conditions and performance | 8 |
| 1.1 Economic background | 8 |
| 1.2 Business performance | 8 |
| 1.3 Segment performance | 12 |
| 2. Earnings, financial and | |
| asset position | 18 |
| 2.1 Earnings position | 18 |
| 2.2 Financial and asset position | 19 |
| 3. Research & development | 21 |
| 4. Employees | 22 |
| 5. Opportunity and risk report | 22 |
| 6. Events after the reporting date | 22 |
| 7. Expected development | 23 |
| Interim financial statements | 24 |
|---|---|
| Income statement | 24 |
| Statement of comprehensive income | 25 |
| Balance sheet | 26 |
| Statement of changes in equity | 28 |
| Cash flow statement | 30 |
| Notes | 32 |
| 1. Segment report | 32 |
| 2. General information | 34 |
| 3. Accounting policies | 34 |
| 4. Changes in the Group | 36 |
| 5. Notes to the income statement | 39 |
| 6. Notes to the balance sheet | 40 |
| 7. Notes on the segment report | 41 |
| 8. Other disclosures | 42 |
As expected, the overall global economic situation stabilized further in the first quarter of 2014. Global growth continued the sustained upward trend that started in mid-2013, despite some headwind from the political situation in the Ukraine, the cold winter in the USA and persistent pressure on exchange rates and share prices in the emerging markets.
In particular Europe and Germany, which are especially important regions for Evonik, registered a further slight recovery. Although economic growth in North America was held back by the extreme winter weather, it was nevertheless still good.
Worldwide, the development of Evonik's end-customer industries was more dynamic in the first quarter of 2014 than a year earlier. As anticipated, output increased considerably year-on-year. In Europe, and especially Germany, favorable weather conditions in the first two months provided additional upward impetus in some end-customer industries.
However, the positive demand situation in the first quarter only had a limited effect on prices in the various end-customer industries. Most prices remained at the low levels seen in the second half of 2013 and were therefore far lower than in the first quarter of 2013.
Despite mounting geopolitical tension, in the first quarter of 2014 Evonik's average raw material prices only increased slightly from the low level recorded in the fourth quarter of 2013.
At the end of March 2014 we reached agreement with Daimler AG on restructuring our lithium-ion activities. This entails the sale of our 50.1 percent interest in Li-Tec Battery GmbH and the 10 percent stake in Deutsche Accumotive GmbH & Co. KG to Daimler AG, which will then be the sole owner of both companies. The shares will probably be transferred in the second quarter of 2014. In view of the planned exit from these activities, we reclassified our lithium-ion business to discontinued operations in September 2013. The revaluation of assets and provisions in connection with this agreement resulted in income after taxes of €21 million in the first quarter of 2014.
Further strong demand for our products was registered in the first quarter of 2014 in a somewhat more positive economic environment. As a consequence of the challenging market conditions for some important products, selling prices remained well below the very high level of the first quarter of 2013, although they did improve slightly compared with year-end 2013. Overall, sales were virtually unchanged and we can report solid adjusted EBITDA. Nevertheless, adjusted EBITDA was considerably lower than in the first quarter of 2013, which was by far the strongest quarter of the year.
•INTERIM MANAGEMENT REPORT • INTERIM FINANCIAL STATEMENTS
Business conditions and performance Business performance
2014 2013
Prior-year figures restated.
The Evonik Group's sales were €3,201 million, in line with the previous year. Higher demand enabled us to achieve slight organic growth of 1 percent despite erosion of selling prices. Adverse currency effects clipped sales by 1 percentage point.
| in % | 1st quarter 2014 |
|---|---|
| Volumes | 5 |
| Prices | –4 |
| Organic sales growth | 1 |
| Exchange rates | –1 |
| Other effects | 0 |
| Total | 0 |
2014 2013
Prior-year figures restated.
Adjusted EBITDA was €463 million, 24 percent below the very good figure for the prior-year period due to the drop in selling prices. The adjusted EBITDA margin therefore declined from 18.9 percent to 14.5 percent.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
| Sales | 3,201 | 3,212 | 0 |
| Adjusted EBITDA | 463 | 606 | –24 |
| Depreciation and amortization | –147 | –142 | |
| Adjusted EBIT | 316 | 464 | –32 |
| Adjustments | –28 | –30 | |
| thereof attributable to | |||
| Restructuring | –5 | –5 | |
| Impairment losses/reversals of impairment losses | –18 | – | |
| Acquisition/divestment of shareholdings | – | – | |
| Other | –5 | –25 | |
| Net interest expense | –76 | –66 | |
| Income before income taxes, continuing operations | 212 | 368 | –42 |
| Income taxes | –63 | –85 | |
| Income after taxes, continuing operations | 149 | 283 | –47 |
| Income after taxes, discontinued operations | 21 | 7 | |
| Income after taxes | 170 | 290 | –41 |
| thereof attributable to non-controlling interests | 4 | –3 | |
| Net income | 166 | 293 | –43 |
| Earnings per share in € | 0.36 | 0.63 | –43 |
Prior-year figures restated.
Adjusted EBIT dropped 32 percent to €316 million, principally as a consequence of lower selling prices.
The adjustments of minus €28 million mainly relate to changes in the valuation of the 49 percent stake in STEAG GmbH, which is recognized at equity. In this connection, an impairment loss of €18 million was taken on the carrying amount of this investment. At the same time, the pro rata guaranteed dividend was recognized in income. Overall, this resulted in expense of €6 million. In addition, the adjustments contain restructuring expenses of €5 million. The prior-year figure of minus €30 million mainly comprised expenses in connection with recognition of the put and call options for the STEAG shares.
Net interest expense was €76 million and contained interest expense of €24 million in connection with one-off factors relating to the establishment of provisions. If these are factored out, there was a considerable year-on-year improvement, chiefly because of the repayment of the Evonik Degussa bond in December 2013. Income before income taxes, continuing operations was 42 percent lower at €212 million. The income tax ratio was in line with the expected level at 30 percent.
Business performance
Income after taxes, discontinued operations1 was €21 million. This item reflects the lithium-ion business and was mainly connected with the divestment agreement. The weak operating performance and the impact of one-off factors on interest expense reduced net income to €166 million.
| 1st quarter | ||||
|---|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
|
| Income before financial result and income taxes a | 279 | 421 | –34 | |
| Result from investments recognized at equity | 9 | 7 | ||
| Other financial income | – | 6 | ||
| EBIT | 288 | 434 | –34 | |
| Adjustments | 28 | 30 | ||
| Adjusted EBIT | 316 | 464 | –32 | |
| Adjusted net interest | –52 | –66 | ||
| Adjusted income before income taxes a | 264 | 398 | –34 | |
| Adjusted income taxes | –74 | –90 | ||
| Adjusted income after taxes a | 190 | 308 | –38 | |
| thereof adjusted income attributable to non-controlling interests | 3 | 3 | ||
| Adjusted net incomea | 187 | 305 | –39 | |
| Adjusted earnings per sharea in € | 0.40 | 0.65 | –39 |
Prior-year figures restated.
a Continuing operations.
Adjusted net income, which reflects the operating performance of the continuing operations, dropped 39 percent to €187 million in the first quarter of 2014. Adjusted earnings per share decreased from €0.65 to €0.40.
Systematic implementation of the On Track 2.0 efficiency enhancement program introduced in 2012 is proceeding well. Measures with annual savings potential of around €300 million out of the target of €500 million set for year-end 2016 are now being implemented. The additional Administration Excellence program launched in fall 2013 to optimize the quality of our Group-wide administration processes is also on schedule. This program should leverage savings of up to €250 million a year by the end of 2016. Initial organizational changes were made in 2013 and further optimization is currently being worked out in detail. Implementation of these measures will start in the second half of 2014, and the majority will be implemented in 2015 and 2016.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
| External sales | 978 | 1,027 | –5 |
| Consumer Specialties Business Unit | 525 | 545 | –4 |
| Health & Nutrition Business Unit | 453 | 482 | –6 |
| Adjusted EBITDA | 187 | 281 | –33 |
| Adjusted EBITDA margin in % | 19.1 | 27.3 | – |
| Adjusted EBIT | 150 | 245 | –39 |
| Capital expenditures | 81 | 61 | 33 |
| Employees as of March 31 | 7,144 | 6,878 | 4 |
Prior-year figures restated.
The Consumer, Health & Nutrition segment's sales dropped 5 percent to €978 million. Excluding negative currency effects, this segment posted a slight organic sales drop as selling prices declined despite higher volumes. Adjusted EBITDA was 33 percent below the high prior-period level at €187 million due to lower selling prices and start-up expenses for new production capacity. The adjusted EBITDA margin was 19.1 percent, down from the previous year's very good level of 27.3 percent.
2014 2013 Prior-year figures restated.
Sales decreased by 4 percent to €525 million in the Consumer Specialties Business Unit. While volume sales of superabsorbents were below the very high level recorded in the first quarter of 2013, almost all other products posted a very pleasing trend. Adjusted EBITDA fell short of the prior-year level, mainly as a result of higher fixed costs and start-up expenses in connection with growth-driven investments.
In the Health & Nutrition Business Unit sales contracted by 6 percent to €453 million. Sales revenues from amino acids for animal nutrition were lower despite higher demand. The main cause of this was a drop in selling prices compared with the high prior-period level. Business with products for the healthcare sector was impaired by the postponement of development projects. The drop in this segment's adjusted EBITDA was principally attributable to lower prices than in the excellent prior-period quarter.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
| External sales | 805 | 771 | 4 |
| Inorganic Materials Business Unit | 366 | 361 | 1 |
| Coatings & Additives Business Unit | 439 | 410 | 7 |
| Adjusted EBITDA | 189 | 172 | 10 |
| Adjusted EBITDA margin in % | 23.5 | 22.3 | – |
| Adjusted EBIT | 160 | 143 | 12 |
| Capital expenditures | 44 | 37 | 19 |
| Employees as of March 31 | 5,933 | 5,806 | 2 |
Sales in the Resource Efficiency segment grew 4 percent to €805 million. Virtually stable selling prices and a substantial hike in volumes led to clear organic sales growth, but this was reduced by negative currency effects. Adjusted EBITDA rose 10 percent to €189 million and the adjusted EBITDA margin improved from 22.3 percent in the prior-year period to 23.5 percent.
2014 2013
Business conditions and performance Segment performance
The Inorganic Materials Business Unit grew sales slightly to €366 million, driven by higher volumes and a slight improvement in selling prices, with a negative effect coming from exchange rates. In particular, the silica and silanes business benefited from strong demand from the automotive and coating industries, enabling it to post higher sales. Matting agents for paints and coatings also did well. Adjusted EBITDA improved thanks to the increase in volume sales and high capacity utilization.
This business unit's sales rose 7 percent to €439 million. Strong demand from the automotive, coatings and construction sectors generated clear volume growth, especially in crosslinkers and oil additives. Adjusted EBITDA therefore increased.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
| External sales | 1,177 | 1,170 | 1 |
| Performance Polymers Business Unit | 461 | 443 | 4 |
| Advanced Intermediates Business Unit | 716 | 727 | –2 |
| Adjusted EBITDA | 111 | 182 | –39 |
| Adjusted EBITDA margin in % | 9.4 | 15.6 | – |
| Adjusted EBIT | 72 | 145 | –50 |
| Capital expenditures | 56 | 50 | 12 |
| Employees as of March 31 | 6,318 | 6,229 | 1 |
The Specialty Materials segment lifted sales by 1 percent to €1,177 million. Excluding exchange rate effects, the segment achieved slight organic sales growth. There was a pleasing increase in volumes but product prices dropped considerably. Adjusted EBITDA was €111 million, well below the high year-back figure, mainly due to lower selling prices. The adjusted EBITDA margin was 9.4 percent, down from 15.6 percent in the first quarter of 2013.
2014 2013
Sales grew 4 percent to €461 million in the Performance Polymers Business Unit. In particular, polyamide 12 products benefited from rising demand. Demand for methacrylates was solid in Europe and North America, but selling prices came under pressure from overcapacity in Asia and persistently weak demand from southern Europe. Adjusted EBITDA was down year-on-year, partly because of higher raw material costs.
Sales in the Advanced Intermediates Business Unit declined by 2 percent to €716 million. Far lower selling prices for performance intermediates (C4 chemistry), especially butadiene, were largely offset by strong volume growth in virtually all products. Adjusted EBITDA fell far short of the good prior-year figure due to the drop in selling prices.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | Change in % |
| External sales | 207 | 204 | 1 |
| Adjusted EBITDA | 51 | 54 | –6 |
| Adjusted EBITDA margin in % | 24.6 | 26.5 | – |
| Adjusted EBIT | 28 | 32 | –13 |
| Capital expenditures | 22 | 21 | 5 |
| Employees as of March 31 | 12,316 | 12,046 | 2 |
Prior-year figures restated.
The Services segment's sales totaled €651 million. Internal sales accounted for €444 million of the total. External sales were up slightly year-on-year at €207 million, while adjusted EBITDA fell slightly to €51 million. This was partly due to scheduled maintenance work at one of our power plants in Marl (Germany).
Sales were virtually unchanged year-on-year at €3,201 million as the increase in volumes was canceled out by lower selling prices and adverse currency effects. As a result of the increase in sales volume, the cost of sales increased 3 percent to €2,314 million. The gross profit on sales therefore decreased by 8 percent to €887 million. Selling and administrative expenses were €466 million, around the same level as in the previous year. To strengthen our innovative capability still further, we raised spending on research and development by 7 percent to €98 million.
Other operating income totaling €173 million mainly includes income from the measurement of derivatives (€68 million) and from currency translation of monetary assets and liabilities (€43 million). The €116 million year-on-year decline in other operating income was caused principally by lower income from currency translation of monetary assets and liabilities and the fact that the prior-year figure included the reversal of provisions. The other operating expenses of €217 million comprised €64 million relating to the measurement of derivatives, €59 million relating to currency translation of monetary assets and liabilities, and €18 million relating to impairment losses on the carrying amount of the investment in STEAG. The decline of €58 million compared with the first quarter of 2013 was mainly due to lower expenses in connection with the first two of these items. Income before financial result and income taxes, continuing operations was €279 million, 34 percent below the corresponding prior-year figure.
The financial result declined to minus €67 million. This figure includes interest expense of €24 million relating to one-off factors in connection with the establishment of provisions. Income before income taxes, continuing operations declined 42 percent to €212 million. After deduction of the lower income taxes, income after income taxes, continuing operations was €149 million, 47 percent less than in the prior-year quarter.
The income after taxes, discontinued operations1 amounting to €21 million related to the lithiumion business, and was mainly connected with the divestment agreement. Overall, the net income of the Evonik Group dropped to €166 million as a result of the weaker operating performance and the impact of one-off factors on interest expense.
Financial debt was €1,647 million on March 31, 2014, €41 million higher than at year-end 2013. Financial assets also increased (€53 million), so the net financial assets as stated on the balance sheet improved by €12 million to €583 million.
| in € million | Mar. 31, 2014 |
Dec. 31, 2013 |
|---|---|---|
| Non-current financial liabilities | –634 | –627 |
| Current financial liabilities | –1,013 | –979 |
| Financial debt a | –1,647 | –1,606 |
| Cash and cash equivalents | 1,575 | 1,527 |
| Current securities | 639 | 635 |
| Other financial assets | 16 | 15 |
| Financial assets a | 2,230 | 2,177 |
| Net financial assets as stated on the balance sheet | 583 | 571 |
| Net financial assets, discontinued operations | 14 | 18 |
| Net financial assets (total) | 597 | 589 |
Prior-year figures restated.
a Excluding derivatives.
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Cash flow from operating activities, continuing operations | 322 | 184 |
| Cash flow from operating activities, discontinued operations | –7 | 4 |
| Cash flow from operating activities | 315 | 188 |
| Cash flow from investing activities, continuing operations | –283 | 150 |
| Cash flow from investing activities, discontinued operations | –1 | 3 |
| Cash flow from investing activities | –284 | 153 |
| Cash flow from financing activities, continuing operations | 16 | –503 |
| Cash flow from financing activities, discontinued operations | – | – |
| Cash flow from financing activities | 16 | –503 |
| Change in cash and cash equivalents | 47 | –162 |
Prior-year figures restated.
The cash flow from operating activities, continuing operations increased by €138 million to €322 million. The drop in income before depreciation, amortization, financial result and income taxes was more than offset, mainly by lower growth in net working capital and lower income tax payments. The cash outflow for operating activities, discontinued operations was €7 million, compared with a cash inflow of €4 million in the previous year. Overall, the cash flow from operating activities increased by €127 million to €315 million.
The cash outflow for investing activities, continuing operations was €283 million, mainly for capital expenditures on property, plant and equipment and for investments in shareholdings. In the prior-year period, outflows for capital expenditures were more than offset by inflows from the sale of securities, resulting in a net cash inflow of €150 million. Together with the corresponding cash flow from the discontinued operations, there was a cash outflow of €284 million for investing activities in the first quarter of 2014, compared with an inflow of €153 million in the prior-year period.
The cash flow from financing activities comprised an inflow of €16 million. In the prior-year period, the dividend payment of €429 million for 2012 resulted in a total cash outflow of €503 million. The dividend of €1.00 per share for 2013 will be paid after the resolution by the Annual Shareholders' Meeting on May 20, 2014.
Capital expenditures increased 17 percent to €209 million. 39 percent of capital expenditures were allocated to the Consumer, Health & Nutrition segment, 27 percent to the Specialty Materials segment, and 21 percent to the Resource Efficiency segment. The Inorganic Materials Business Unit, which has been raising global capacity for precipitated silicas since 2010, opened an extended production facility in Rayong (Thailand) in mid-March 2014. Growth in South-East Asia is driven principally by tires that reduce fuel consumption and life-science applications. The Coatings & Additives Business Unit is completing new production facilities for isophorone and isophorone diamine in Shanghai (China). Investment in these plants amounts to more than €100 million. Isophorone chemicals increase the lifecycle of, for example, heavy-duty surfaces, and also facilitate environment-friendly coating technologies.
Investment in financial assets increased to €42 million and mainly comprises the acquisition of Silbond Corporation, Weston (Michigan, USA), a specialized supplier of silicic acid esters (TEOS). Silicic acid esters are a special group of functional silanes used in a wide variety of high-growth applications, for example, in the electronics industry. The acquisition opens the door for our Inorganic Materials Business Unit to supply TEOS from local production, especially to customers in North America, and to participate in future growth in the market for silicic acid esters.
Total assets were €16.4 billion as of March 31, 2014, €0.5 billion higher than at year-end 2013. Non-current assets increased by €0.3 billion to €10.1 billion. Current assets rose slightly to €6.3 billion as trade accounts receivable were higher. Equity decreased by €0.3 billion to €6.5 billion, principally due to the reduction in the discount rate for pension provisions1. The equity ratio therefore declined from 43.0 percent to 39.9 percent.
Our intensive research and development endeavors continued in the first quarter of 2014 and R&D expenses increased 7 percent to €98 million.
The Performance Polymers Business Unit launched CYROLITE Protect 2, the second product in its new range of PMMA molding compounds with antimicrobial properties. Products from the CYROLITE Protect product line are used in medical devices. Their antimicrobial capabilities relate to a wide range of different micro-organisms commonly found in medical institutions. For example, they can prevent hospital-acquired infections.
In recent years, the Health & Nutrition Business Unit has been working on a new source of methionine specifically for shrimp and crustaceans. This innovative product is now being scaled up for industrial production: Evonik is building the world's first production plant for AQUAVI Met-Met in Antwerp (Belgium). This plant is scheduled for completion by year-end 2015 and investment is in the lower double-digit million euro range. AQUAVI Met-Met is added to the feed used in aquaculture. It reduces consumption of expensive fishmeal and improves water quality by raising the efficiency of the feed. AQUAVI Met-Met therefore makes an important contribution to the sustainability of aquaculture. Evonik is already the market leader in amino acids as additives for fish feed, especially for salmonids (salmon, trout). AQUAVI Met-Met gives us access to an attractive new market for shrimp and crustaceans. Over the past ten years there has been double-digit growth in market volume and further dynamic growth is expected for the future.
As of March 31, 2014, the Evonik Group had 33,651 employees. 33,059 of them were employed in the continuing operations, an increase of 64 compared with year-end 2013.
| Mar. 31, 2014 |
Dec. 31, 2013 |
|
|---|---|---|
| Consumer, Health & Nutrition | 7,144 | 7,150 |
| Resource Efficiency | 5,933 | 5,854 |
| Specialty Materials | 6,318 | 6,268 |
| Services | 12,316 | 12,192 |
| Other operations | 1,348 | 1,531 |
| Continuing operations | 33,059 | 32,995 |
| Discontinued operations | 592 | 655 |
| Evonik | 33,651 | 33,650 |
As an international Group with a diversified portfolio of specialty chemicals, Evonik is exposed to a wide range of opportunities and risks. The risk categories and principal individual opportunities and risks relating to our earnings, financial and asset position, and the structure of our risk management system are described in detail in the opportunity and risk report for 2013.
With the economic situation remaining uncertain, we regularly and systematically monitor and analyze the markets, sectors and growth prospects of relevance for our segments. Based on current price trends in our Consumer, Health & Nutrition and Specialty Materials segments, we see fewer opportunities for the current year than in our assessment at the end of 2013, while the risk situation is unchanged. As in the past, there are no risks that could jeopardize the continued existence of the Evonik Group. Looking at material individual companies, the risk situation for our lithium-ion business has declined considerably following the agreement to sell our shares in Li-Tec Battery GmbH to Daimler AG.
No material events have occurred since the reporting date.
Looking at the global economic background, we still expect global growth to be higher in 2014 than in 2013. Alongside the stepwise recovery in Europe, there are some challenges, especially in the emerging markets, and increasing risk comes from geopolitical tension, above all in the Ukraine. Despite the continued upturn in demand and the resulting volume growth, the decline in producer prices observed in 2013 will not be reversed in all end-customer industries in 2014.
The expected cyclical recovery occurred at the start of this year, especially in Europe and Germany, which are significant for our volume sales. As anticipated, in the first quarter of 2014 the pace of growth declined further in the emerging markets, especially China. We therefore only expect these regions to make a slight contribution to the recovery of the global economy.
We are sticking to the forecast we made at the start of this year for global economic conditions in 2014 as a whole. Our forecast is still based on the following assumptions:
Based on these overall economic conditions, we are reiterating our outlook for the full year. We still anticipate that sales will rise slightly (2013: €12.7 billion1) and that adjusted EBITDA will be between €1.8 billion and €2.1 billion (2013: €2.0 billion).
The positive volume trend should continue, driven by the completion of our first growth investments. For some major business activities we still assume that in 2014 selling prices will be below the average for 2013 as price levels were positively influenced by higher prices in the first six months of 2013.
Further relief on the cost front should come from the On Track 2.0 efficiency enhancement program. In addition, we expect to see the first positive effects of the new Administration Excellence program to optimize administrative structures. Downside factors could result from ramp-up expenses for growth investments and negative currency effects.
This report contains forward-looking statements based on the present expectations, assumptions and forecasts made by the Executive Board and the information available to it. These forward-looking statements do not constitute a guarantee of future developments and earnings expectations. Future performance and developments depend on a wide variety of factors which contain a number of risks and unforeseeable factors and are based on assumptions that may prove incorrect.
1 Restated for IFRS 11 Joint Arrangements.
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Sales | 3,201 | 3,212 |
| Cost of sales | –2,314 | –2,243 |
| Gross profit on sales | 887 | 969 |
| Selling expenses | –315 | –314 |
| Research and development expenses | –98 | –92 |
| General administrative expenses | –151 | –156 |
| Other operating income | 173 | 289 |
| Other operating expenses | –217 | –275 |
| Income before financial result and income taxes, continuing operations | 279 | 421 |
| Interest income | 6 | 10 |
| Interest expense | –82 | –76 |
| Result from investments recognized at equity | 9 | 7 |
| Other financial income | – | 6 |
| Financial result | –67 | –53 |
| Income before income taxes, continuing operations | 212 | 368 |
| Income taxes | –63 | –85 |
| Income after taxes, continuing operations | 149 | 283 |
| Income after taxes, discontinued operations | 21 | 7 |
| Income after taxes | 170 | 290 |
| thereof attributable to | ||
| Non-controlling interests | 4 | –3 |
| Shareholders of Evonik Industries AG (net income) | 166 | 293 |
| Earnings per share in € (basic and diluted) | 0.36 | 0.63 |
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Income after taxes | 170 | 290 |
| Comprehensive income that will be reclassified subsequently to profit or loss | –12 | 35 |
| Unrealized gains/losses on available-for-sale securities | 1 | –7 |
| Gains/losses on hedging instruments | –17 | –15 |
| Currency translation adjustment | –1 | 51 |
| Deferred taxes | 5 | 6 |
| Comprehensive income that will not be reclassified subsequently to profit or loss | –448 | 5 |
| Remeasurement of the net defined benefit liability for defined benefit pension plans | –641 | 8 |
| Deferred taxes | 193 | –3 |
| Other comprehensive income after taxes | –460 | 40 |
| Total comprehensive income | –290 | 330 |
| thereof attributable to | ||
| Non-controlling interests | 3 | –3 |
| Shareholders of Evonik Industries AG | –293 | 333 |
| Total comprehensive income attributable to shareholders of Evonik Industries AG | –293 | 333 |
| thereof attributable to | ||
| Continuing operations | –313 | 320 |
| Discontinued operations | 20 | 13 |
| in € million | Mar. 31, 2014 |
Dec. 31, 2013 |
|---|---|---|
| Intangible assets | 3,054 | 3,038 |
| Property, plant and equipment | 4,882 | 4,822 |
| Investment property | 10 | 10 |
| Investments recognized at equity | 867 | 878 |
| Financial assets | 148 | 150 |
| Deferred tax assets | 1,041 | 837 |
| Other income tax assets | 14 | 13 |
| Other receivables | 32 | 30 |
| Non-current assets | 10,048 | 9,778 |
| Inventories | 1,613 | 1,594 |
| Other income tax assets | 172 | 188 |
| Trade accounts receivable | 1,768 | 1,626 |
| Other receivables | 304 | 278 |
| Financial assets | 751 | 748 |
| Cash and cash equivalents | 1,575 | 1,527 |
| 6,183 | 5,961 | |
| Assets held for sale | 124 | 144 |
| Current assets | 6,307 | 6,105 |
| Total assets | 16,355 | 15,883 |
Balance sheet
27
| in € million | Mar. 31, 2014 |
Dec. 31, 2013 |
|---|---|---|
| Issued capital | 466 | 466 |
| Capital reserve | 1,168 | 1,165 |
| Accumulated income | 5,255 | 5,547 |
| Treasury shares | –9 | – |
| Accumulated other comprehensive income | –431 | –420 |
| Equity attributable to shareholders of Evonik Industries AG | 6,449 | 6,758 |
| Equity attributable to non-controlling interests | 76 | 78 |
| Equity | 6,525 | 6,836 |
| Provisions for pensions and other post-employment benefits | 3,971 | 3,331 |
| Other provisions | 873 | 800 |
| Deferred tax liabilities | 419 | 412 |
| Other income tax liabilities | 156 | 148 |
| Financial liabilities | 636 | 627 |
| Other payables | 80 | 81 |
| Non-current liabilities | 6,135 | 5,399 |
| Other provisions | 999 | 979 |
| Other income tax liabilities | 183 | 158 |
| Financial liabilities | 1,063 | 1,037 |
| Trade accounts payable | 1,063 | 1,089 |
| Other payables | 314 | 282 |
| 3,622 | 3,545 | |
| Liabilities associated with assets held for sale | 73 | 103 |
| Current liabilities | 3,695 | 3,648 |
| Total equity and liabilities | 16,355 | 15,883 |
| in € million | Issued capital | Capital reserve | Accumulated income | |
|---|---|---|---|---|
| As of December 31, 2012 | 466 | 1,165 | 3,940 | |
| Changes pursuant to IAS 8 | – | – | 1 | |
| As of January 1, 2013 | 466 | 1,165 | 3,941 | |
| Capital increases/decreases | – | – | – | |
| Dividend distribution | – | – | –429 | |
| Changes in ownership interests in subsidiaries without loss of control |
– | – | – | |
| Income after taxes | – | – | 293 | |
| Other comprehensive income after taxes | – | – | 5 | |
| Total comprehensive income | – | – | 298 | |
| Other changes | – | – | 1 | |
| As of March 31, 2013 | 466 | 1,165 | 3,811 | |
| As of January 1, 2014 | 466 | 1,165 | 5,547 | |
| Capital increases/decreases | – | – | – | |
| Purchase of treasury shares | – | – | – | |
| Share-based payment | – | 3 | – | |
| Dividend distribution | – | – | – | |
| Changes in ownership interests in subsidiaries without loss of control |
– | – | – | |
| Income after taxes | – | – | 166 | |
| Other comprehensive income after taxes | – | – | –448 | |
| Total comprehensive income | – | – | –282 | |
| Other changes | – | – | –10 | |
| As of March 31, 2014 | 466 | 1,168 | 5,255 |
| Statement of changes in equity | ||
|---|---|---|
| Total equity | Attributable to non-controlling interests |
Attributable to shareholders of Evonik Industries AG |
Accumulated other comprehensive income |
Treasury shares |
|---|---|---|---|---|
| 5,469 | 111 | 5,358 | –213 | – |
| –9 | – | –9 | –10 | – |
| 5,460 | 111 | 5,349 | –223 | – |
| – | – | – | – | |
| –429 | – | –429 | – | – |
| –2 | –2 | – | – | – |
| 290 | –3 | 293 | – | – |
| – | 40 | 35 | – | |
| –3 | 333 | 35 | – | |
| – | – | –1 | – | |
| 5,359 | 106 | 5,253 | –189 | – |
| 6,836 | 78 | 6,758 | –420 | – |
| – | – | – | – | |
| –9 | – | –9 | – | –9 |
| 3 | – | 3 | – | – |
| –5 | – | – | – | |
| – | – | – | – | |
| 170 | 4 | 166 | – | – |
| –460 | –1 | –459 | –11 | – |
| –290 | 3 | –293 | –11 | – |
| – | –10 | – | – | |
| 6,525 | 76 | 6,449 | –431 | –9 |
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Income before financial result and income taxes, continuing operations | 279 | 421 |
| Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets |
147 | 143 |
| Gains/losses on the disposal of non-current assets | – | 1 |
| Change in inventories | –19 | –126 |
| Change in trade accounts receivable | –131 | –186 |
| Change in trade accounts payable and current advance payments received from customers | 36 | 5 |
| Change in provisions for pensions and other post-employment benefits | –32 | –33 |
| Change in other provisions | 36 | –17 |
| Change in miscellaneous assets/liabilities | 14 | 67 |
| Cash outflows for interest | –10 | –15 |
| Cash inflows from interest | 5 | 5 |
| Cash inflows from dividends | 24 | 1 |
| Cash inflows/outflows for income taxes | –27 | –82 |
| Cash flow from operating activities, continuing operations | 322 | 184 |
| Cash flow from operating activities, discontinued operations | –7 | 4 |
| Cash flow from operating activities | 315 | 188 |
| Cash outflows for investments in intangible assets, property, plant and equipment, investment property |
–258 | –216 |
| Cash outflows for investments in shareholdings | –39 | –2 |
| Cash inflows from divestments of intangible assets, property, plant and equipment, investment property |
2 | 13 |
| Cash inflows/outflows from divestment of shareholdings | 16 | –7 |
| Cash inflows/outflows relating to securities, deposits and loans | –4 | 362 |
| Cash flow from investing activities, continuing operations | –283 | 150 |
| Cash flow from investing activities, discontinued operations | –1 | 3 |
| Cash flow from investing activities | –284 | 153 |
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Cash outflows for dividends to shareholders of Evonik Industries AG | – | –429 |
| Cash outflows for dividends to non-controlling interests | –3 | – |
| Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control |
– | –2 |
| Cash outflows for the purchase of treasury shares | –6 | – |
| Cash inflows from the addition of financial liabilities | 112 | 48 |
| Cash outflows for repayment of financial liabilities | –87 | –120 |
| Cash flow from financing activities, continuing operations | 16 | –503 |
| Cash flow from financing activities, discontinued operations | – | – |
| Cash flow from financing activities | 16 | –503 |
| Change in cash and cash equivalents | 47 | –162 |
| Cash and cash equivalents as of January 1 | 1,572 | 793 |
| Change in cash and cash equivalents | 47 | –162 |
| Changes in exchange rates and other changes in cash and cash equivalents | –1 | 7 |
| Cash and cash equivalents as of March 31 | 1,618 | 638 |
| Cash and cash equivalents included in assets held for sale | –43 | –50 |
| Cash and cash equivalents as on the balance sheet as of March 31 | 1,575 | 588 |
| Operating segments | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Consumer, Health & Nutrition |
Resource Efficiency | Specialty Materials | |||||||
| in € million | 2014 | 2013 | 2014 | 2013 | 2014 | 2013 | |||
| External sales | 978 | 1,027 | 805 | 771 | 1,177 | 1,170 | |||
| Internal sales | 18 | 17 | 21 | 15 | 31 | 32 | |||
| Total sales | 996 | 1,044 | 826 | 786 | 1,208 | 1,202 | |||
| Adjusted EBITDA | 187 | 281 | 189 | 172 | 111 | 182 | |||
| Adjusted EBITDA margin in % | 19.1 | 27.3 | 23.5 | 22.3 | 9.4 | 15.6 | |||
| Adjusted EBIT | 150 | 245 | 160 | 143 | 72 | 145 | |||
| Capital expenditures | 81 | 61 | 44 | 37 | 56 | 50 | |||
| Financial investments | 1 | 1 | 40 | – | – | 2 | |||
| Employees as of March 31 | 7,144 | 6,878 | 5,933 | 5,806 | 6,318 | 6,229 |
Prior-year figures restated.
| Germany | Other European countries |
North America | |||||
|---|---|---|---|---|---|---|---|
| in € million | 2014 | 2013 | 2014 | 2013 | 2014 | 2013 | |
| External sales | 754 | 726 | 1,097 | 1,071 | 541 | 576 | |
| Goodwill as of March 31a | 1,542 | 1,557 | 541 | 540 | 300 | 304 | |
| Other intangible assets, property, plant and equipment, investment property as of March 31a |
2,749 | 2,977 | 477 | 476 | 716 | 701 | |
| Capital expenditures | 77 | 60 | 18 | 18 | 24 | 24 | |
| Employees as of March 31 | 21,256 | 20,737 | 2,800 | 2,735 | 3,772 | 3,783 |
Prior-year figures restated.
a Non-current assets according to IFRS 8.33 b.
Notes Segment report
| Services | Total reporting segments |
Corporate, other | operations, consolidation | Total Group | (continuing operations) | ||
|---|---|---|---|---|---|---|---|
| 2014 | 2013 | 2014 | 2013 | 2014 | 2013 | 2014 | 2013 |
| 207 | 204 | 3,167 | 3,172 | 34 | 40 | 3,201 | 3,212 |
| 444 | 443 | 514 | 507 | –514 | –507 | – | – |
| 651 | 647 | 3,681 | 3,679 | –480 | –467 | 3,201 | 3,212 |
| 51 | 54 | 538 | 689 | –75 | –83 | 463 | 606 |
| 24.6 | 26.5 | 17.0 | 21.7 | – | – | 14.5 | 18.9 |
| 28 | 32 | 410 | 565 | –94 | –101 | 316 | 464 |
| 22 | 21 | 203 | 169 | 6 | 9 | 209 | 178 |
| – | – | 41 | 3 | 1 | – | 42 | |
| 12,316 | 12,046 | 31,711 | 30,959 | 1,348 | 1,195 | 33,059 | 32,154 |
| Central and | Total Group | ||||||
|---|---|---|---|---|---|---|---|
| South America | Asia-Pacific | Middle East, Africa | (continuing operations) | ||||
| 2014 | 2013 | 2014 | 2013 | 2014 | 2013 | 2014 | |
| 185 | 205 | 547 | 556 | 77 | 78 | 3,201 | |
| 26 | 27 | 237 | 262 | – | 1 | 2,646 | |
| 93 | 45 | 1,255 | 926 | 10 | 11 | 5,300 | |
| 20 | 11 | 70 | 64 | – | 1 | 209 | |
| 527 | 447 | 4,562 | 4,341 | 142 | 111 | 33,059 |
Evonik Industries AG is an international specialty chemicals company headquartered in Germany. It also has investments in residential real estate and the energy sector.
The present condensed and consolidated interim financial statements (consolidated interim financial statements) of Evonik Industries AG and its subsidiaries (referred to jointly as Evonik or the Group) as of March 31, 2014, have been prepared in accordance with the provisions of IAS 34 Interim Financial Reporting, and in application of Section 315 a Paragraph 1 of the German Commercial Code (HGB) using the International Financial Reporting Standards (IFRS) and comply with these standards. The IFRS comprise the standards (IFRS, IAS) issued by the International Accounting Standards Board (IASB), London (UK) and the interpretations (IFRIC, SIC) of the IFRS Interpretations Committee (IFRS IC), as adopted by the European Union.
The consolidated interim financial statements as of March 31, 2014 are presented in euros. The reporting period is January 1 to March 31, 2014. All amounts are stated in millions of euros (€ million) except where otherwise indicated. The basis for the consolidated interim financial statements comprises the consolidated financial statements for the Evonik Group as of December 31, 2013, which should be referred to for further information.
The accounting and consolidation principles applied in these consolidated interim financial statements are the same as those used for the consolidated financial statements as of December 31, 2013, with the exception of changes resulting from application of new or revised accounting standards that are applicable for the first time in fiscal 2014.
Since January 1, 2014, Evonik has applied IFRS 10 Consolidated Financial Statements and IFRS 11 Joint Arrangements, which the IASB published in May 2011. IFRS 12 Disclosure of Interests in Other Entities, which was published at the same time, will result in extended disclosures in the notes to the consolidated financial statements for the first time as of December 31, 2014.
IFRS 10 replaces the guidelines on control and consolidation contained in IAS 27 Consolidated and Separate Financial Statements and SIC-12 Consolidation—Special Purpose Entities. The new standard alters the definition of control so that the same principles are applied to all companies to determine a relationship of control. A parent company is deemed to control an entity if it is exposed, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. This definition is supported by extensive application guidance. The new standard does not alter the previous core principle set out in IAS 27 that consolidated financial statements present the parent company and its subsidiaries as a single economic entity, nor does it alter the consolidation procedure. IAS 27 is to be renamed Separate Financial Statements and will in future only contain the unchanged rulings on the preparation of separate financial statements. SIC-12 will be withdrawn. First-time application of IFRS 10 did not have any impact on the scope of consolidation as of January 1, 2014.
IFRS 11 supersedes IAS 31 Interests in Joint Ventures. As a result of the amended definitions in IFRS 11, there are now two types of joint arrangements: joint operations and joint ventures. Joint ventures may now only be recognized using the equity method. The previous option of pro rata consolidation has been abolished. This change does not affect Evonik as the company only used the equity method in the past. Companies involved in joint operations are required to recognize their share of the assets, liabilities, revenue and expenses from such operations. As a result of first-time application of IFRS 11, effective January 1, 2014 Evonik was required to reclassify a company with three subsidiaries allocated to the Consumer, Health & Nutrition segment that was previously recognized at equity as a joint operation.
The following tables show the impact of the retrospective application of IFRS 11 on the prior-year figures.
| 1st quarter 2013 | |
|---|---|
| in € million | Impact of change |
| Sales | –40 |
| Cost of sales | 52 |
| Result from investments recognized at equity | –6 |
| Income taxes | –2 |
| Income after taxes | 4 |
| Dec. 31, 2013 | |
|---|---|
| in € million | Impact of change |
| Non-current assets | –42 |
| thereof investments recognized at equity | –82 |
| Current assets | 27 |
| thereof cash and cash equivalents | 9 |
| Total assets | –15 |
| Equity | –11 |
| Non-current liabilities | 2 |
| Current liabilities | –6 |
| Total equity and liabilities | –15 |
| 1st quarter 2013 | |
|---|---|
| in € million | Impact of change |
| Cash flow from operating activities | –25 |
| Cash flow from investing activities | –2 |
| Cash flow from financing activities | – |
The scope of consolidation changed as follows in the reporting period:
| Number of companies | Germany | Other countries |
Total |
|---|---|---|---|
| Evonik Industries AG and consolidated subsidiaries | |||
| As of December 31, 2013 | 45 | 102 | 147 |
| Acquisitions | – | 1 | 1 |
| Other companies consolidated for the first time | – | 1 | 1 |
| Intragroup mergers | –1 | –2 | –3 |
| As of March 31, 2014 | 44 | 102 | 146 |
| Joint operations | |||
| As of December 31, 2013 | – | – | – |
| Changes due to first-time application of IFRS 11 | 2 | 2 | 4 |
| As of March 31, 2014 | 2 | 2 | 4 |
| Investments recognized at equity | |||
| As of December 31, 2013 | 7 | 10 | 17 |
| Changes due to first-time application of IFRS 11 | –1 | – | –1 |
| As of March 31, 2014 | 6 | 10 | 16 |
| 52 | 114 | 166 |
This section provides a more detailed overview of the changes in the scope of consolidation in the reporting period, divided into acquisitions and divestments.
On February 28, 2014 Evonik acquired all shares in Silbond Corporation, Weston (Michigan, USA) from Silbond Holdings LLC, Bloomfield Hills (Delaware, USA). Silbond Corporation is a leading supplier of silicic acid esters, a special group of functional silanes used in a wide variety of future-oriented applications, for example, in the electronics industry and in chemical applications. The business has been integrated into the Resource Efficiency segment.
37
First-time consolidation of Silbond Corporation was based on a provisional purchase price allocation. The impact on the balance sheet as of the date of initial consolidation was as follows:
| Fair value |
|---|
| 22 |
| 7 |
| 3 |
| 1 |
| –8 |
| –1 |
| 20 |
| 18 |
| 38 |
The purchase price was settled out of cash and cash equivalents. Transaction costs of less than €1 million relating to this acquisition are included in other operating expenses. The goodwill is not tax-deductible and mainly comprises the expected future benefits of assets that were not individually identifiable or for which recognition is not permitted, for example, anticipated synergies or the workforce.
Due to the short period for which it has been part of the Group and the size of the business, the contributions made by Silbond Corporation to sales and earnings were not material, either in the reporting period or on a pro forma basis in the period from January 1, 2014.
In the reporting period, agreements were signed in connection with the restructuring of the lithium-ion business and the divestment of the STOKO Skin Care business. These transactions have not yet been closed; see Note 4.3.
The assets and liabilities of the lithium-ion business and the STOKO Skin Care business were reclassified as held for sale for the first time in the third quarter of 2013. The development of these transactions since December 31, 2013 is outlined below.
Under an agreement dated March 31, 2014, Evonik has divested the 50.1 percent stake in Li-Tec Battery GmbH, Kamenz (Germany), and the 10 percent stake in Deutsche Accumotive GmbH & Co. KG, Kirchheim unter Teck (Germany), which were part of the lithium-ion business, to Daimler AG, Stuttgart (Germany). The companies will remain classified as held for sale until the transaction is closed. It was agreed not to divulge the purchase prices. The wholly owned subsidiary Evonik Litarion GmbH, Kamenz (Germany) did not form part of this transaction. In the segment report, the lithium-ion activities are included in other operations.
The STOKO Skin Care business assigned to the Consumer, Health & Nutrition segment was sold to Deb Holdings Ltd, Denby (UK) under an agreement dated March 19, 2014. It was agreed not to disclose the purchase price. The assets and liabilities of this business will remain classified as held for sale until closing of the asset deal.
IFRS 5 Non-current Assets Held for Sale and Discontinued Operations sets out the accounting principles to be used in such cases and their presentation in the consolidated financial statements.
Assets held for sale and the associated liabilities have to be stated separately from other assets and liabilities on the balance sheet. The amounts recognized for these assets and liabilities in the previous year do not have to be restated.
Businesses whose assets and liabilities have been classified as held for sale may also meet the criteria for classification as discontinued operations, especially if a separate, significant business area is to be disposed of. The income and expenses of such discontinued operations have to be stated separately from those of continuing operations in the income statement. The cash flows also have to be stated separately. The prior-period figures have to be restated in the income statement and the cash flow statement. The lithium-ion business meets the criteria for classification as a discontinued operation.
The following table shows the main impact of the discontinued operations on the income statement. No divestment gains/losses were recorded in the reporting period. The agreement with Daimler AG had a positive overall impact of €29 million on the income from discontinued operations. This comprises the revaluation of the assets held for sale, and one-off income from the adjustment of agreements and of a provision set up in the previous year.
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Income | 60 | 76 |
| Lithium-ion business | 60 | 12 |
| Former Real Estate segment | – | 64 |
| Expenses | –31 | –68 |
| Lithium-ion business | –31 | –26 |
| Former Real Estate segment | – | –42 |
| Operating income before income taxes, discontinued operations | 29 | 8 |
| Lithium-ion business | 29 | –14 |
| Former Real Estate segment | – | 22 |
| Income taxes | –8 | –1 |
| Lithium-ion business | –8 | 1 |
| Former Real Estate segment | – | –2 |
| Operating income after taxes, discontinued operations | 21 | 7 |
| Lithium-ion business | 21 | –13 |
| Former Real Estate segment | – | 20 |
The following table shows the assets held for sale and the associated liabilities after all consolidation steps:
| in € million | Mar. 31, 2014 |
Dec. 31, 2013 |
|---|---|---|
| Intangible assets | 5 | 5 |
| Property, plant and equipment | 8 | 9 |
| Financial assets | 10 | – |
| Deferred tax assets | 4 | 3 |
| Inventories | 32 | 46 |
| Trade accounts receivable | 20 | 34 |
| Other receivables | 2 | 2 |
| Cash and cash equivalents | 43 | 45 |
| Assets held for sale | 124 | 144 |
| Provisions for pensions and other post-employment benefits | 9 | 8 |
| Other provisions | 17 | 38 |
| Deferred tax liabilities | 2 | 2 |
| Financial liabilities | 33 | 36 |
| Trade accounts payable | 10 | 16 |
| Other payables | 2 | 3 |
| Liabilities associated with assets held for sale | 73 | 103 |
| 1st quarter | ||
|---|---|---|
| in € million | 2014 | 2013 |
| Income from the measurement of derivatives (excluding interest rate derivatives) | 68 | 96 |
| Income from currency translation of monetary assets and liabilities | 43 | 87 |
| Other income | 62 | 106 |
| 173 | 289 | |
| thereof adjustments | 16 | 4 |
In the first quarter of 2014, the other income of €62 million included income from the guaranteed dividend on the remaining 49 percent of shares in STEAG GmbH (STEAG), Essen (Germany), income from non-core businesses, and insurance refunds. The decline in other income was principally due to the fact that the prior-year figure contained reversals of provisions.
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | |
| Losses on the measurement of derivatives (excluding interest rate derivatives) | 64 | 133 | |
| Losses on currency translation of monetary assets and liabilities | 59 | 70 | |
| Impairment losses | 20 | 4 | |
| Other expense | 74 | 68 | |
| 217 | 275 | ||
| thereof adjustments | 44 | 34 | |
€18 million of the impairment losses relates to the valuation of the remaining 49 percent of shares in STEAG. The other expense of €74 million in the first quarter of 2014 related, among other things, to outsourcing, projects for the acquisition and divestment of companies and business operations, non-core businesses, commission expenses, and legal and consultancy fees.
Including one-off factors totaling €24 million in connection with the establishment of provisions, interest expense rose €6 million year-on-year to €82 million. Excluding the one-off factors, there was a significant drop in interest expense year-on-year, mainly because of the redemption of the Evonik Degussa bond in December 2013.
In 2013 the Executive Board of Evonik Industries AG decided to purchase shares in the company, utilizing the resolution adopted by the Annual Shareholders' Meeting of Evonik Industries AG on March 11, 2013 authorizing it to buy back shares in the company in accordance with Section 71 Paragraph 1 No. 8 of the German Stock Corporation Act (AktG). The Supervisory Board has approved this share buy-back program, which relates to the share-based employee participation program (employee share program) Share.2014 launched by Evonik Industries AG in March 2014. Employees of Evonik Industries AG and certain subordinated Group companies, and the management of certain subordinated Group companies in Germany, Belgium and the USA were eligible for this program. Every participant could acquire shares up to a maximum value of €4,000 (US\$5,400 in the USA), conditional upon the purchase of at least two shares. Evonik granted bonus shares in a ratio of two to one for personal investments of up to €500 (U\$660 in the USA). In addition, the company granted every participant further bonus shares of up to €110 (U\$150 in the USA). The maximum subsidy therefore totaled €360 (US\$480 in the USA). The subscription period ended on March 28, 2014 and the shares purchased or granted under Share.2014 must be held until December 31, 2016.
The employee share program is a share-based payment program with settlement in equity instruments that are vested with effect from the end of the subscription period.
By March 31, 2014 Evonik Industries AG had purchased 328,960 ordinary shares on the capital market at an average price of €27.19 per share. That is 0.07 percent of the capital stock. The ordinary shares purchased by the company are included in the calculation of earnings per share. The employee share program resulted in personnel expense of €3 million, which was recognized in full in the reporting period as the entitlements are vested.
Compared with December 31, 2013, provisions for pensions and other post-employment benefits increased by a total of €640 million to €3,971 million as of March 31, 2014, and include €641 million recognized in equity with no impact on income after taxes. This increase was mainly attributable to the reduction in the discount rate used for Germany and the euro-zone countries from 3.75 percent to 3.25 percent. The discount rate for Germany and the euro-zone countries is determined from market data for AA-rated euro-denominated corporate bonds, whose market yields had declined as of March 31, 2014. The change in provisions for pensions and other post-employment benefits and the related deferred tax assets is reflected in a reduction of €448 million in other comprehensive income from the remeasurement of the net defined benefit liability for defined benefit plans, which is recognized in equity under accumulated income.
The Executive Board of Evonik Industries AG decides on the allocation of resources and evaluates the earnings power of the Group's operations on the basis of the operating segments (subsequently referred to as segments). The operating activities are divided into business units within the segments. The reporting based on segments reflects the Group's internal organizational and reporting structure (management approach).
Until the end of 2013, adjusted EBIT was the main earnings parameter that could be influenced by the segment management. As from 2014, the main parameter used to measure operating performance is adjusted EBITDA.
The table shows a reconciliation from adjusted EBITDA for the reporting segments to income before income taxes for the Group's continuing operations.
to income before income taxes, continuing operations
| 1st quarter | |||
|---|---|---|---|
| in € million | 2014 | 2013 | |
| Adjusted EBITDA, reporting segments | 538 | 689 | |
| Adjusted EBITDA, other operations | –13 | –42 | |
| Adjusted EBITDA, Corporate | –65 | –51 | |
| Consolidation | 1 | – | |
| Less discontinued operations | 2 | 10 | |
| Adjusted EBITDA, Corporate, other operations, consolidation | –75 | –83 | |
| Adjusted EBITDA | 463 | 606 | |
| Depreciation, amortization, impairment losses/reversal of impairment losses | –166 | –143 | |
| Depreciation, amortization, impairment losses/reversals of impairment losses included in adjustments |
19 | 1 | |
| Adjusted EBIT | 316 | 464 | |
| Adjustments | –28 | –30 | |
| Net interest expense | –76 | –66 | |
| Income before income taxes, continuing operations | 212 | 368 |
The following table shows a breakdown of the column Corporate, other operations, consolidation in the segment report by operating segments:
| discontinued operations) | Other operations (including | Corporate, consolidation, less discontinued operations |
consolidation | Corporate, other operations, | ||
|---|---|---|---|---|---|---|
| 1st quarter | 1st quarter | 1st quarter | ||||
| in € million | 2014 | 2013 | 2014 | 2013 | 2014 | 2013 |
| External sales | 47 | 51 | –13 | –11 | 34 | 40 |
| Internal sales | 54 | 55 | –568 | –562 | –514 | –507 |
| Total sales | 101 | 106 | –581 | –573 | –480 | –467 |
| Adjusted EBITDA | –13 | –42 | –62 | –41 | –75 | –83 |
| Adjusted EBITDA margin in % |
– | – | – | – | – | – |
| Adjusted EBIT | –17 | –48 | –77 | –53 | –94 | –101 |
| Capital expenditures | 6 | 12 | – | –3 | 6 | 9 |
| Financial investments | 1 | – | – | – | 1 | – |
Breakdown of Corporate, other operations, consolidation
The column headed other operations includes the interests in Vivawest and STEAG, which are recognized at equity, and the lithium-ion business, which is classified as held for sale. In the column Corporate, consolidation less discontinued operations, an adjustment is made for the lithiumion business. This business is not included in the column Corporate, other operations, consolidation because only continuing operations are reported here.
The fair value determination is based on the 3-level hierarchy stipulated by IFRS 13 Fair Value Measurement:
The following table shows the assets and liabilities that were measured at fair value on a recurring basis after initial recognition on the balance sheet:
| Fair value based on | |||||
|---|---|---|---|---|---|
| in € million | Level 1 | Level 2 | Level 3 | ||
| Assets recognized at fair value | 644 | 69 | 107 | 820 | |
| Securities and similar claims | 644 | – | – | 644 | |
| Receivables from derivatives | – | 69 | 107 | 176 | |
| Liabilities recognized at fair value | – | –22 | –30 | –52 | |
| Liabilities from derivatives | – | –22 | –30 | –52 |
Level 2 derivatives comprise currency, interest rate and commodity derivatives whose fair value was determined on the basis of the exchange rates at the European Central Bank, observed interest rate structure curves, observed commodity prices, and observed credit default premiums. The discount effect on these derivatives is negligible.
The fair value resulting from the measurement of the put option and the call option for the remaining 49 percent shareholding in STEAG is allocated to Level 3. Recognized mathematical finance methods are used to model the observed change in the market value of the underlying.
There were no reclassifications to other levels in the reporting period.
| in € million | Receivables from derivatives |
Liabilities from derivatives |
Total |
|---|---|---|---|
| As of January 1, 2014 | 113 | –32 | 81 |
| Additions | – | – | – |
| Gains or losses in the reporting period | –6 | 2 | –4 |
| Other operating income | – | 2 | 2 |
| Other operating expenses | –6 | – | –6 |
| As of March 31, 2014 | 107 | –30 | 77 |
As of March 31, 2014, the net value of the put option and the call option for the remaining 49 percent of the shares in STEAG was €77 million. The central factors influencing the valuation were the formula-based option strike price and an estimate of the fair value of the shares in STEAG. If the fair value of these shares had been 10 percent lower on March 31, 2014, the net value of the options would have been €44 million higher and would have resulted in an additional gain of the same amount. A 10 percent increase in the fair value of the shares would have reduced the net value of the options by €45 million, resulting in a corresponding additional loss.
As of March 31, 2014, the assets and liabilities recognized at fair value on a non-recurring basis totaled €42 million. These are contained in assets held for sale and the associated liabilities. The net value derived from the loss-free valuation of these assets and liabilities is allocated to Level 2. The main input factor for the valuation was the expected proceeds from sale less the costs to sell.
The following overview shows the carrying amounts and fair values of all financial assets and liabilities:
| Mar. 31, 2014 | ||
|---|---|---|
| in € million | Carrying amount |
Fair value |
| Financial assets | 899 | 899 |
| Other investments | 8 | 8 |
| Loans | 28 | 28 |
| Securities and similar claims | 644 | 644 |
| Receivables from finance leases | – | – |
| Receivables from derivatives | 176 | 176 |
| Other financial assets | 43 | 43 |
| Trade accounts receivable | 1,768 | 1,768 |
| Cash and cash equivalents | 1,575 | 1,575 |
| Mar. 31, 2014 | ||
|---|---|---|
| in € million | Carrying amount |
Fair value |
| Financial liabilities | 1,699 | 1,751 |
| Bonds | 1,244 | 1,279 |
| Liabilities to banks | 346 | 363 |
| Loans from non-banks | 34 | 34 |
| Liabilities from finance leases | 3 | 3 |
| Liabilities from derivatives | 52 | 52 |
| Other financial liabilities | 20 | 20 |
| Trade accounts payable | 1,063 | 1,063 |
Notes Other disclosures 45
There has not been any material change in contingent assets and liabilities since the consolidated annual financial statements as of December 31, 2013.
There has not been any material change in related party transactions since December 31, 2013.
The dividend for fiscal 2013 will be paid after the resolution of the Annual Shareholders' Meeting on May 20, 2014. In 2013, the dividend for fiscal 2012 was paid in the first quarter.
No material events have occurred since the reporting date.
Essen, April 28, 2014
Evonik Industries AG The Executive Board
Dr. Engel Wessel Wohlhauser Wolf
| Event | Date |
|---|---|
| Annual Shareholders' Meeting 2014 | May 20, 2014 |
| Interim Report Q2 2014 | July 31, 2014 |
| Interim Report Q3 2014 | October 30, 2014 |
Evonik Industries AG Rellinghauser Straße 1 – 11 45128 Essen Germany www.evonik.com
Communications/Board Office phone +49 201 177-3388 fax +49 201 177-3181 [email protected]
phone +49 201 177-3146 fax +49 201 177-3148 [email protected]
KNSK Werbeagentur GmbH HGB Hamburger Geschäftsberichte GmbH & Co. KG
The English version is a translation of the German version and is provided for information only.
Evonik Industries AG Rellinghauser Straße 1– 11 45128 Essen Germany www.evonik.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.